GlassScriptPhysician profile
Abdul R Zanabli
NPI 1487752093
$30,726.89
in general payments reported to CMS, 2019-2025
24 companies · $3,113 in 2025
The $3,113 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,341 · 2020: $6,893 · 2021: $4,721 · 2022: $3,153 · 2023: $1,308 · 2024: $4,198 · 2025: $3,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181 · Consulting Fee: $2,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,100 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.18 |
| Consulting Fee | $2,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,100.00 |
| Education | $137.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,801.50 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $4,328.88 | 2022-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $3,501.70 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $516.18 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $507.19 | 2022-2025 | |
| Vifor Pharma, INC. | $475.40 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $454.21 | 2022-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $368.75 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $331.50 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.30 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $205.40 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $170.52 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $121.98 | 2025 | Auvelity |
| Recor Medical INC | $103.58 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Fresenius USA Marketing, INC. | $75.18 | 2022-2025 | Velphoro, Velphoro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $71.71 | 2025 | Ultomiris |
| Nxstage Medical, INC. | $71.62 | 2019 | |
| Opko Pharmaceuticals, LLC | $65.41 | 2024-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $58.21 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $50.95 | 2022-2025 | Lupkynis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.00 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $45.95 | 2022-2023 | Benlysta |
| Scpharmaceuticals INC. | $19.21 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Zanabli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.